MEDBOT-B's stock surged 6.53% during intraday trading on Wednesday, driven by a combination of a major analyst upgrade, a key regulatory milestone, and robust financial targets.

The rally was primarily fueled by UBS upgrading the surgical robotics company from "Neutral" to "Buy" and significantly raising its target price. The investment bank highlighted the firm's explosive overseas growth, with revenue surging 287% year-over-year and sales of its Toumai surgical robot increasing more than fivefold.

Concurrently, the company achieved a significant milestone as its self-developed Honghu orthopedic surgical robot obtained European CE certification, marking it as the first domestically developed joint replacement surgical robot to reach this standard. The sector also continues to benefit from supportive policies in China promoting the adoption of surgical robots in hospitals. Management aims to double total revenue in 2026 and expects overseas revenue to exceed 80% of the total, potentially leading to breakeven in the first half of the year.